Adjuvant darolutamide prolongs survival in metastatic, hormone-sensitive prostate cancer

Researchers from a phase 3 clinical trial report that addition of the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy significantly prolongs the survival of men with metastatic, hormone-sensitive prostate cancer. The findings appeared on February 18, 2022 in the NEJM/New England Journal of Medicine. As background, the authors noted that darolutamide therapy has previously been associated with increased overall survival […]